Crinetics (NASDAQ: CRNX) CSO sells shares to cover RSU tax

Rhea-AI Filing Summary

Crinetics Pharmaceuticals Chief Scientific Officer Stephen F. Betz reported selling a total of 10,612 shares of common stock on March 16, 2026 in open-market transactions. One block of 6,371 shares was sold at a volume-weighted average price of $37.11 per share, and another 4,241 shares at $37.77 per share.

According to the footnotes, these sales were made to cover his tax withholding obligations upon the vesting of previously granted restricted stock units and were executed by a broker under a pre-arranged Rule 10b5-1 trading plan. After these transactions, Betz directly holds 137,101 shares of Crinetics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Betz Stephen F.

(Last) (First) (Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		S(1)		6,371	D	$37.11(2)	141,342	D
Common Stock	03/16/2026		S(1)		4,241	D	$37.77(3)	137,101	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, March 4, 2024, and February 20, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.

2. The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.11 per share. The range of sales prices on the transaction date was $36.42 to $37.38 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.

3. The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.77 per share. The range of sales prices on the transaction date was $37.42 to $38.23 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.

Remarks:

	/s/ Tobin Schilke, as attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CRNX Chief Scientific Officer Stephen Betz report?

Stephen F. Betz reported selling 10,612 shares of Crinetics Pharmaceuticals common stock. The sales occurred on March 16, 2026, in open-market transactions at volume-weighted average prices of $37.11 and $37.77 per share, as disclosed in the Form 4 filing.

Why did CRNX Chief Scientific Officer Stephen Betz sell shares on March 16, 2026?

The shares were sold to cover Stephen F. Betz’s tax withholding obligations from vesting restricted stock units. The Form 4 states the disposition was executed by a broker under instructions in a pre-arranged Rule 10b5-1 trading plan adopted by Betz.

How many CRNX shares did Stephen Betz sell and at what prices?

Stephen Betz sold 10,612 Crinetics Pharmaceuticals shares in two blocks. One sale covered 6,371 shares at a volume-weighted average price of $37.11, and another 4,241 shares at a volume-weighted average price of $37.77, with specified intraday price ranges.

How many CRNX shares does Stephen Betz hold after the reported sales?

After the reported March 16, 2026 transactions, Stephen F. Betz directly holds 137,101 shares of Crinetics Pharmaceuticals common stock. This post-transaction holding figure is explicitly stated in the Form 4 as the total shares following the final reported sale.

Were Stephen Betz’s CRNX share sales under a Rule 10b5-1 trading plan?

Yes. The Form 4 footnotes state the disposition was effected by a broker pursuant to instructions in a Rule 10b5-1 trading plan. Such plans are pre-arranged trading programs that schedule trades in advance, often for tax or diversification purposes.